Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Banner Alzheimer's Institute
-
Phoenix, Arizona, United States, 85006
- Banner Good Samaritan Medical Center
-
Sun City, Arizona, United States, 85351
- Banner Boswell Medical Center
-
Sun City, Arizona, United States, 85351
- Sun Health Research Institute
-
-
California
-
San Francisco, California, United States, 94158
- University of California, San Francisco
-
San Francisco, California, United States, 94118
- University of California, San Francisco
-
San Francisco, California, United States, 94117
- University of California, San Francisco
-
San Francisco, California, United States, 94117
- University of California - San Francisco
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University School Of Medicine
-
New Haven, Connecticut, United States, 06511
- Yale-New Haven Hospital
-
New Haven, Connecticut, United States, 06509
- General Clinical Research Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- General Clinical Research Center
-
Washington, District of Columbia, United States, 20057
- GUMC
-
-
Florida
-
Hallandale Beach, Florida, United States, 33009
- MD Clinical
-
West Palm Beach, Florida, United States, 33407
- Palm Beach Neurology - Premiere Research Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
St. Louis, Missouri, United States, 63108
- Washington University School of Medicine
-
St. Louis, Missouri, United States, 63108
- Barnes-Jewish Hospital
-
St. Louis, Missouri, United States, 63110
- Barrnes-Jewish Hospital at Washington University
-
-
New Jersey
-
Eatontown, New Jersey, United States, 07724
- Memory Enhancement Center of America, Inc.
-
Edison, New Jersey, United States, 08837
- Pharmcare USA
-
-
New York
-
New York, New York, United States, 10032
- CUMC Research Pharmacy
-
New York, New York, United States, 10032
- Columbia Univ/Taub Institute Irving Ctr for Clinical Researc
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Butler Hospital
-
-
Vermont
-
Bennington, Vermont, United States, 05201
- The Memory Clinic
-
Bennington, Vermont, United States, 05201
- The Pharmacy
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of mild to moderate Alzheimer's disease
- Age 50-85
- Mini Mental State Examination (MMSE) 16-26 Other criteria apply
Exclusion Criteria:
- Significant Neurological Disease
- Major psychiatric disorder
- Clinically significant systemic illness Other exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
ACC-001
|
IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
|
|
Other: 2
QS-21
|
IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
|
|
Other: 3
Diluent: Phosphate Buffered Saline
|
IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
|
|
Experimental: 4
ACC-001
|
IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)
Time Frame: approximately 110 weeks, including a 6-week screening period, 52 weeks of dosing and 54 weeks for follow-up after the last dose
|
An AE was any untoward, undesired, or unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study drug or in a sponsor's clinical study.
The event did not need to be causally related to the study drug or the clinical studies.
A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
approximately 110 weeks, including a 6-week screening period, 52 weeks of dosing and 54 weeks for follow-up after the last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
Time Frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
|
The lower limit of quantification (LLOQ) was 100 U/mL and when the assay result was below LLOQ (100 U/mL), 50 U/mL was imputed for IgG.
|
Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
|
|
GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
Time Frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
|
The LLOQ was 50 U/mL and when the assay result was below LLOQ (50 U/mL), 25 U/mL was imputed for IgM.
|
Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
|
|
Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)
Time Frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
|
IgG subtypes were not assessed
|
Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 3134K1-2201
- B2571005 (Other Identifier: Alias Study Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.